

PTO/SB/81 (01-09)
Approved for use through 11/30/2011. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY OR REVOCATION OF POWER OF ATTORNEY WITH A NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td>Patent Number</td><td>6,074,642</td></tr> <tr><td>Issue Date</td><td>June 13, 2000</td></tr> <tr><td>First Named Inventor</td><td>Yi Wang</td></tr> <tr><td>Title</td><td>THE USE OF ANTIBODIES SPECIFIC TO HUMAN COMPLEMENT COMPONENT C5 FOR THE TREATMENT OF GLOMERULONEPHRITIS</td></tr> <tr><td>Art Unit</td><td>1644</td></tr> <tr><td>Examiner Name</td><td>Phillip Gambel</td></tr> <tr><td>Attorney Docket No.</td><td>ALEX-GIP-001</td></tr> </table>	Patent Number	6,074,642	Issue Date	June 13, 2000	First Named Inventor	Yi Wang	Title	THE USE OF ANTIBODIES SPECIFIC TO HUMAN COMPLEMENT COMPONENT C5 FOR THE TREATMENT OF GLOMERULONEPHRITIS	Art Unit	1644	Examiner Name	Phillip Gambel	Attorney Docket No.	ALEX-GIP-001
Patent Number	6,074,642														
Issue Date	June 13, 2000														
First Named Inventor	Yi Wang														
Title	THE USE OF ANTIBODIES SPECIFIC TO HUMAN COMPLEMENT COMPONENT C5 FOR THE TREATMENT OF GLOMERULONEPHRITIS														
Art Unit	1644														
Examiner Name	Phillip Gambel														
Attorney Docket No.	ALEX-GIP-001														

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ A Power of Attorney is submitted herewith.
OR
☒ I hereby appoint Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith: 28120
OR
☐ I hereby appoint Practitioner(s) named below as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith:

Practitioner(s) Name	Registration Number	Practitioner(s) Name	Registration Number

Please recognize or change the correspondence address for the above-identified application to:

☒ The address associated with the above-mentioned Customer Number:
OR
☐ The address associated with Customer Number:
OR

☐ Firm or Individual Name:

Address:

City: State: Zip:

Country: Telephone: Email:

I am the:

☐ Applicant/Inventor.
OR
☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) (Form PTO/SB/96) submitted herewith or filed on _____

SIGNATURE of Applicant or Assignee of Record

Signature	Date	Telephone
<i>Stephen A. Saxe</i>	June 12, 2012	(203) 271-8289
Name	ASSOC. GEN. COUNSEL & EXEC. P.R., J.P., ALEXION PHARM., INC.	
Title and Company		

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☒ *Total of 1 forms are submitted.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-6800, on the date shown below.

Dated: 6/13/12 873-6500 Signature: *Ginny Blundell* (Ginny Blundell)

30672110_1

1

PTO/SB/98 (07-09)

Approved for use through 07/31/2012. OMB 0651-0081
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Alexion Pharmaceuticals, Inc.Application No./Patent No.: 6,074,642 Filed/Issue Date: June 13, 2000Titled: THE USE OF ANTIBODIES SPECIFIC TO HUMAN COMPLEMENT COMPONENT C5 FOR
THE TREATMENT OF GLOMERULONEPHRITISAlexion Pharmaceuticals, Inc., a
(Name of Assignee)corporation
(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest in;
2. ☐ an assignee of less than the entire right, title, and interest in
(The extent (by percentage) of its ownership interest is _____ %); or
3. ☐ an assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)
the patent application/patent identified above by virtue of either:
- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was
recorded in the United States Patent and Trademark Office at Reel 007038,
Frame 0416, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:
1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
- ☐ Additional documents in the chain of title are listed on a supplemental sheet(s).
- ☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the
assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

(NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment
Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08)

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Stephen A. Saxe
SignatureJune 13, 2012
DateSTEPHEN A. SAXE
Printed or Typed NameASSOC. GEN. COUNSEL &
Title
EXEC. DIR., I.P.I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and
Trademark Office, facsimile no. (571) 273-8300, on the date shown below.Dated: 6/13/12 6500 Signature: Ginny Bundell (Ginny Bundell)

30672243_1